In the ordinary course of business, the Company enters into agreements with Contract Research Organizations ("CROs"), Contract Manufacturing Organizations ("CMOs") and strategic manufacturing partners. Certain arrangements include non-cancellable purchase commitments and minimum purchase obligations extending beyond the current reporting period. These commitments are generally not recognized in the consolidated balance sheet until the related goods or services are received, unless recognition of a liability is required under applicable U.S. GAAP, including when a loss contingency is probable and reasonably estimable.



	2026	2027	2028	Thereafter	Total
	(Amounts in USD million)
Clinical development commitments (CRO agreements)	9.1	27.8	20.7	13.5	71.1
Manufacturing and supply commitments (CMO agreements)	20.7	22.7	18.4		61.7
Total contractual commitments	29.8	50.5	39.1	13.5	132.9

Clinical development commitments primarily represent remaining contractual obligations under agreements with contract research organizations and other service providers supporting the Company’s clinical programs, including amounts committed under executed change orders.

Manufacturing and supply commitments primarily represent obligations under the Company’s strategic manufacturing arrangements with Sanofi and Fareva supporting clinical, regulatory and potential commercial supply of VIASKIN® Peanut. These commitments include the Company’s arrangements with Fareva Amboise related to manufacturing readiness and dedicated production capacity, including the Letter of Intent, as amended, and the amendment to the Services Agreement covering additional production batches. They also include the PDS Services Agreement and related Binding Commercial Term Sheet with Fareva La Vallée for the establishment of dedicated PDS manufacturing capabilities and associated transfer services, as well as the Company’s other contractual manufacturing and supply obligations with Sanofi and Fareva.